Patents by Inventor Thorsten Melcher
Thorsten Melcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7060275Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTP?) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTP?, PTP? SM1 and PTP? SM2.Type: GrantFiled: August 28, 2003Date of Patent: June 13, 2006Assignee: AGY Therapeutics, Inc.Inventors: Sabine Mueller, Thorsten Melcher, Daniel Chin
-
Publication number: 20060014801Abstract: The invention provides methods for improving cognitive function in a subject by administering (R)-(?)-5-methyl-1-nicotinoyl-2-pyrazoline (MNP) or an analog to a subject in need of such treatment. The invention is useful for treatment of cognitive impairment such as mild cognitive impairment (MCI) as well as other conditions.Type: ApplicationFiled: February 14, 2005Publication date: January 19, 2006Applicant: The Johns Hopkins UniversityInventors: Michela Gallagher, Pauline Lund, Joel Selcher, Thorsten Melcher
-
Publication number: 20050260132Abstract: The present invention relates to a method of inhibiting growth of tumor cells which overexpress a receptor protein tyrosine phosphatase zeta (PTP?) by treatment of the cells with antibodies which recognize PTP? and/or inhibit PTP? function. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTP?, PTP? SM1 and PTP? SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.Type: ApplicationFiled: March 31, 2005Publication date: November 24, 2005Inventors: Daniel Chin, Erik Foehr, Sabine Mueller, Thorsten Melcher
-
Patent number: 6924109Abstract: Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilize RNA interference techniques in the validation process.Type: GrantFiled: April 3, 2002Date of Patent: August 2, 2005Assignee: AGY Therapeutics, Inc.Inventors: Thorsten Melcher, Keith Charles McFarland, Li Gan, Shiming Ye, Mirella Gonzalez-Zulueta
-
Publication number: 20050074400Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTP?) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTP?, PTP? SM1 and PTP? SM2.Type: ApplicationFiled: August 28, 2003Publication date: April 7, 2005Inventors: Sabine Mueller, Thorsten Melcher, Daniel Chin
-
Publication number: 20050074831Abstract: The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a serine/threonine protein phosphatase (PSTP), e.g., PP2A. The present invention provides methods for screening a PSTP agonist or antagonist that modulates NMDA-R signaling. The present invention also provide methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.Type: ApplicationFiled: March 11, 2003Publication date: April 7, 2005Inventors: Jasna Jerecic, Janice Williams, Jean Bucaria, Thorsten Melcher
-
Publication number: 20050053936Abstract: Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilize RNA interference techniques in the validation process.Type: ApplicationFiled: October 17, 2002Publication date: March 10, 2005Inventors: Thorsten Melcher, Keith McFarland, Li Gan, Shiming Ye, Mirella Gonzalez-Zulueta
-
Patent number: 6841351Abstract: Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilized RNA interference techniques in the validation process.Type: GrantFiled: October 19, 2001Date of Patent: January 11, 2005Assignee: AGY Therapeutics, Inc.Inventors: Li Gan, Mirella Gonzalez-Zulueta, Kristin Anton, Richa Wilson, Thorsten Melcher, Daniel Chin
-
Publication number: 20040072275Abstract: The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a protein tyrosine phosphatase (PTP). The present invention provides methods for screening a PTP agonist or antagonist that modulates NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.Type: ApplicationFiled: August 1, 2003Publication date: April 15, 2004Inventors: Kalev Kask, Thorsten Melcher, Nikolich Karoly
-
Patent number: 6670138Abstract: The present invention identifies a gene whose gene product provides a protective effect against neurological disorders or neuronal injuries. Further, the invention provides methods for diagnosing or assessing an individual's susceptibility to a neuronal injury such as stroke. Also provided are therapeutic methods for treating patients, and methods for prophylactically treating individuals susceptible to various neurological disorders or neuronal injuries. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have suffered or are at risk to suffer such disorders or injuries.Type: GrantFiled: October 31, 2001Date of Patent: December 30, 2003Assignee: AGY Therapeutics, Inc.Inventors: Mirella Gonzalez-Zulueta, Mehrdad Shamloo, K.C. McFarland, Daniel Chin, Tadeusz Wieloch, Thorsten Melcher
-
Patent number: 6660483Abstract: The invention relates to a human phospholipase C expressed in the brain (B-PLC) and induced in response to ischemic brain tissue. The inventions provides methods and reagents useful for diagnosis and treatment of hypoxic-ischemic brain insult such as stroke.Type: GrantFiled: October 13, 2000Date of Patent: December 9, 2003Assignee: AGY Therapeutics, Inc.Inventors: Kalev Kask, Thorsten Melcher, Daniel J. Chin
-
Publication number: 20030118585Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTP&zgr;) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.Type: ApplicationFiled: October 17, 2001Publication date: June 26, 2003Applicant: AGY TherapeuticsInventors: Sabine Muller, Thorsten Melcher, Daniel Chin
-
Publication number: 20030092071Abstract: The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a protein tyrosine phosphatase (PTP), e.g., PTPL1. The present invention provides methods for screening a PTP agonist or antagonist that modulates NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling. The present invention further provides methods for isolating PTPL1 from a biological preparation.Type: ApplicationFiled: September 18, 2002Publication date: May 15, 2003Inventors: Jasna Jerecic, Steven Braithwaite, Kalev Kask, Jenkuei Liu, Thorsten Melcher
-
Publication number: 20030082570Abstract: Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilize RNA interference techniques in the validation process.Type: ApplicationFiled: April 3, 2002Publication date: May 1, 2003Inventors: Thorsten Melcher, K. C. McFarland, Li Gan, Shiming Ye, Mirella Gonzalez-Zulueta
-
Patent number: 6521414Abstract: The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a protein tyrosine phosphatase (PTP), e.g., PTPL1. The present invention provides methods for screening a PTPL1 agonist or antagonist that modulates NMDA-R signaling. The present invention also provide methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling. The present invention further provides methods for isolating PTPL1 from a biological preparation.Type: GrantFiled: January 30, 2001Date of Patent: February 18, 2003Assignee: AGY Therapeutics, Inc.Inventors: Thorsten Melcher, Kalev Kask
-
Publication number: 20030027168Abstract: Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilized RNA interference techniques in the validation process.Type: ApplicationFiled: October 19, 2001Publication date: February 6, 2003Applicant: AGY Therapeutics, Inc.Inventors: Li Gan, Mirella Gonzalez-Zulueta, Kristin Anton, Richa Wilson, Thorsten Melcher, Daniel Chin
-
Publication number: 20020172958Abstract: The present invention identifies a gene whose gene product provides a protective effect against neurological disorders or neuronal injuries. Further, the invention provides methods for diagnosing or assessing an individual's susceptibility to a neuronal injury such as stroke. Also provided are therapeutic methods for treating patients, and methods for prophylactically treating individuals susceptible to various neurological disorders or neuronal injuries. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have suffered or are at risk to suffer such disorders or injuries.Type: ApplicationFiled: October 31, 2001Publication date: November 21, 2002Applicant: AGY Therapeutics, Inc.Inventors: Mirella Gonzalez-Zulueta, Mehrdad Shamloo, K.C. McFarland, Daniel Chin, Tadeusz Wieloch, Thorsten Melcher
-
Publication number: 20020146370Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to human protein tyrosine phosphatase-zeta (PTP&xgr;) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.Type: ApplicationFiled: March 23, 2001Publication date: October 10, 2002Applicant: AGY THERAPEUTICSInventors: Sabine Mueller, Thorsten Melcher, Daniel J. Chin
-
Patent number: 6455026Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents that specifically bind to human protein tyrosine phosphatase-zeta (PTP&zgr;) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.Type: GrantFiled: March 23, 2001Date of Patent: September 24, 2002Assignee: AGY Therapeutics, Inc.Inventors: Sabine Mueller, Thorsten Melcher, Daniel J. Chin
-
Publication number: 20010049348Abstract: The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a protein tyrosine phosphatase (PTP), e.g., PTPL1. The present invention provides methods for screening a PTP agonist or antagonist that modulates NMDA-R signaling. The present invention also provide methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling. The present invention further provides methods for isolating PTPL1 from a biological preparation.Type: ApplicationFiled: January 30, 2001Publication date: December 6, 2001Inventors: Thorsten Melcher, Kalev Kask